M. Ruddy

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase <scp>II</scp> a open‐label trial and subsequent phase <scp>III</scp> open‐label extension

Michael J. Cork, Diamant Thaçi, Lawrence F. Eichenfield et al. · British Journal of Dermatology · 2019 · 145 citations · Full text

Medicine, Dermatology, Pharmacology +15

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to &lt;6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

Amy S. Paller, Elaine C. Siegfried, Eric L. Simpson et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 87 citations · Full text

Medicine, Dermatology, Pediatrics +16

The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1β), and complement

Brian Leaker, Vlad Malkov, Robin Mogg et al. · Mucosal Immunology · 2016 · 77 citations · Full text

Life Sciences, Immunology, Pathobiology +15

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*

Yan Zhao, Liming Wu, Qianjin Lu et al. · British Journal of Dermatology · 2021 · 71 citations · Full text

Medicine, Dermatology, Immunology +13

Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

Martin Desrosiers, Leda Mannent, Nikhil Amin et al. · Rhinology Journal · 2021 · 70 citations · Full text

Medicine, Otolaryngology, Pharmacotherapy +17